In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

CVD Prevention in clinical practice (European Guidelines on)

ESC Clinical Practice Guidelines

The present guidelines represent an evidence-based consensus of the 6th European Joint Task Force  involving 10 professional societies.This document has been developed to support healthcare professionals communicating with individuals about their cardiovascular (CV) risk and the benefits of a healthy lifestyle and early modification of their CV risk. In addition, the guidelines provide tools for healthcare professionals to promote population-based strategies and integrate these into national or regional prevention frameworks and to translate these in locally delivered healthcare services, in line with the recommendations of the World Health Organization (WHO) global status report on non-communicable diseases 2010.

Primary care
Prevention
Dyslipidemia
Guidelines version available to download
Published in 2016
Reference 2016 EHJ doi/10.1093/eurheartj/ehw106
Published in 2016
Reference 2016 EHJ doi:10.1093/eurheartj/ehw106/-/DC1
Published in 2016
Reference 2016 Pocket Guidelines CVD PREV
Published in 2016
Reference 2016 Essential Messages CVD Prevention
Published in 2016
Reference 2016 Slides CVD PREV
Published in 2016
Reference 2016 CVD Prevention Summary in General Practice
Published in 2016
Reference 2016 CME Questions CVD Prev
Published in 2012
Reference 2012 European Heart Journal (2012) 33, 1635–1701
Published in 2012
Reference 2012 Addenda: Web Tables-EHJ 2012:doi:10.1093/eurheartj/ehs165
Table of contents: Full Text (ESC Clinical Practice Guidelines)
  1. What is cardiovascular disease prevention?

        1.1 Definition and rationale

        1.2 Development of the 6th Joint Task Force guidelines

        1.3 Cost-effectiveness of prevention      

  1. Who will benefit from prevention? When and how to assess risk and prioritize

        2.1 Estimation of total cardiovascular risk

        2.2 When to assess total cardiovascular risk?

        2.3 How to estimate total cardiovascular risk?

        2.4 Other risk markers

        2.5 Relevant groups

3a. How to intervene at the individual level: risk factor intervention

       3a.1 Behaviour change

       3a.2 Psychosocial factors

       3a.3 Sedentary behaviour and physical activity

       3a.4 Smoking intervention

       3a.5 Nutrition

       3a.6 Body weight

       3a.7 Lipid control

       3a.8 Diabetes mellitus (type 2 and type 1)

       3a.9 Hypertension

       3a.10 Antiplatelet therapy

       3a.11 Adherence to medication

3b. How to intervene at the individual level: disease specific intervention
      Atrial fibrillation, coronary artery disease, chronic heart failure, cerebrovascular disease, peripheral       artery disease (web addenda)

3c. How to intervene at the population level

      3c.1 Introduction (healthy lifestyle promotion)

      3c.2 Population-based approaches to diet

      3c.3 Population-based approaches to physical activity

      3c.4 Population-based approaches to smoking and other tobacco use

      3c.5 Alcohol abuse protection

      3c.6 Healthy environment

4a. Where to intervene at the individual level

      4a.1 Clinical settings and stakeholders

      4a.2 How to monitor preventive activities

4b. Where to intervene at the population level

      4b.1 Government and public health

      4b.2 Non-governmental organizations

Appendix

References


 

 

 

Back to top
European Society
of Cardiology

Les Templiers
2035 Route des Colles
CS 80179 BIOT
06903 Sophia Antipolis
Cedex France

Phone: 33.4.92.94.76.00